Replies to post #82208 on Regen BioPharma Inc (RGBP)

[AfricanTrader]

The number of outstanding shares are irrelevant when evaluating the value of RGBP patents.

First they have to determine the value of patents. That is based on many factors including future projection.

If they place the value at $10 billions, all they have to do is work the math based on outstanding shares.

[gotinearly]

Winner, what happens to the shares in a buyout depends s on the deal. Typically the shares will be cancelled in exchange for cash (if applicable) and stock of the new company (if applicable). The only time I can think of that the shares would not be cancelled is if they kept rgbp as a subsidiary. I don't think subsidiary is probable, however